Leerink Raises Eli Lilly (LLY) Price Target to $1,232
Leerink raised its price target on Eli Lilly (LLY) to $1,232 from $1,119, while keeping an Outperform rating, reflecting a positive outlook on the stock.
Key Numbers
Leerink Partners raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,232 from $1,119, maintaining an Outperform rating. The update, dated June 25, reinforces the stock's status as a safe pick for beginners in 2026.
Rating Change
- Previous Price Target: $1,119
- New Price Target: $1,232
- Rating: Outperform (unchanged)
Analyst Rationale
While no specific reasons were detailed, the upgrade reflects positive expectations for Eli Lilly's performance, supported by its strong drug portfolio, particularly in diabetes and obesity treatments.
Context
Eli Lilly is considered a safe stock for beginners in 2026, according to earlier reports. The stock trades near $1,200, with other analysts also holding positive views. The update follows a strong Q1 performance.
What to Make of It
The price target increase signals analyst confidence in Eli Lilly's growth prospects, but investors should weigh risks such as competition and regulatory pricing.
Frequently Asked Questions
Found this useful? Share it